Effect of switching from etelcalcetide to upacicalcet in maintenance hemodialysis patients receiving treatment for secondary hyperparathyroidism

DOI Web Site Web Site 1 Citations 18 References
  • Yoshida Masaki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital Asakuracho Yoshida Clinic
  • Masuda Misaki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Oshikawa Taishi
    Dialysis and Nephrology Center, Sanshikai Toho Hospital Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine
  • Sakurai Noriyuki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Harigai Takako
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Kobatake Keiko
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Yoshida Hiroaki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Kobayashi Satsuki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Matsumoto Takayuki
    Dialysis and Nephrology Center, Sanshikai Toho Hospital
  • Ueki Kazue
    Dialysis and Nephrology Center, Sanshikai Toho Hospital

Bibliographic Information

Other Title
  • 二次性副甲状腺機能亢進症治療中の維持血液透析患者におけるエテルカルセチドからウパシカルセトへの切り替えによる影響の検討
  • ニジセイ フクコウジョウセン キノウ コウシンショウ チリョウ チュウ ノ イジ ケツエキ トウセキ カンジャ ニ オケル エテルカルセチド カラ ウパシカルセト エ ノ キリカエ ニ ヨル エイキョウ ノ ケントウ

Search this article

Abstract

<p>［Objective］This study aimed to investigate the efficacy and safety of switching from etelcalcetide to upacicalcet for secondary hyperparathyroidism in maintenance hemodialysis patients.［Methods］We retrospectively evaluated 90 hemodialysis patients (65 males, 25 females) undergoing treatment for secondary hyperparathyroidism who were switched from etelcalcetide to upacicalcet. The patients were divided into 4 groups according to the etelcalcetide dose：low-dose group (2.5 mg), medium-dose group (5 mg), high-dose group (7.5-10 mg), and very-high-dose group (15 mg). When switching, upacicalcet was started at 25 μg in all patients, and then the dose was adjusted to maintain whole-parathyroid hormone (PTH) levels within 35-150 pg/mL. Whole-PTH, phosphate, and calcium (Ca) levels were measured every 4 weeks.［Results］After switching, in high-dose and very-high-dose groups, Whole-PTH and corrected Ca levels increased, but subsequently decreased to pre-switch levels with increasing doses of upacicalcet. The target achievement rates of Whole-PTH levels after 48 weeks were：100, 88.7, 86.7, and 71.4％ in low-, medium-, high-, and very-high-dose groups, respectively, which were higher than before the switch. No adverse events such as hypocalcemia were observed.［Conclusion］Switching to upacicalcet in maintenance hemodialysis patients treated with etelcalcetide for secondary hyperparathyroidism involves no particular safety or efficacy concerns. However, careful attention should be paid to transient increases in Whole-PTH and corrected Ca levels when switching from more than 7.5 mg of etelcalcetide to 25 μg of upacicalcet.</p>

Journal

Citations (1)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top